Immunovaccine Inc. said today that the European Medicines Agency granted orphan drug designation for its immunotherapy candidate for ovarian cancer in the E.U.
Orphan drug designation is granted to medicines intended for disease with a prevalence no greater than 5 in 10,000 people. According to the Nova Scotia-based company, ovarian cancer affects 3 per 10,000 people in the European Union or 15,000 women at any given time.
Get the full story at our sister site, Drug Delivery Business News.
The post Immunovaccine’s targeted ovarian cancer therapy wins orphan drug status in EU appeared first on MassDevice.
from MassDevice http://ift.tt/2gHYMv9
Cap comentari:
Publica un comentari a l'entrada